Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 16/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | PLD2 | O14939 | 2/20 | 0.42 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2364412 | 0.84 | HTR2C (0.50) | SLC6A9HTR2COPRM1SLC6A5KCNH2 | |
| SCHEMBL5561878 | 0.84 | SLC6A9 (0.58) | SLC6A9OPRM1SLC6A5KCNH2PLD2 | |
| SCHEMBL1138347 | 0.84 | SLC6A9 (0.58) | SLC6A9OPRM1SLC6A5KCNH2PLD2 | |
| SCHEMBL5556903 | 0.84 | SLC6A9 (0.58) | SLC6A9OPRM1SLC6A5KCNH2PLD2 | |
| Hydrochloric Acid SCHEMBL2336054 | 0.83 | HTR2C (0.51) | SLC6A9HTR2COPRM1SLC6A5 | |
| Hydrochloric Acid SCHEMBL5562493 | 0.83 | SLC6A9 (0.57) | SLC6A9OPRM1SLC6A5KCNH2PLD2 | |
| SCHEMBL5556904 | 0.81 | SLC6A9 (0.55) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL1138335 | 0.81 | SLC6A9 (0.56) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL9963254 | 0.80 | SLC6A9 (0.59) | SLC6A9OPRM1SLC6A5KCNH2PLD2 | |
| SCHEMBL4339185 | 0.78 | SLC6A9 (0.42) | SLC6A9OPRM1SLC6A5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716147-B1 | DIAZA-SPIROPIPERIDINE DERIVATIVES AS INHIBITORS OF GLYCINE TRANSPORTER 1 AND GLYCINE TRANSPORTER 2 | HOFFMANN LA ROCHE (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-7265126-B2 | Diaza-spiropiperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050154000-A1 | Diaza-spiropiperidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154000-A1 | Diaza-spiropiperidine derivatives | AVPR1A, AVPR1B, QDPR | SLC6A9 1752/4885HTR2C 556/4885OPRM1 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.